Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer

BACKGROUND: High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases; however, there are challenges associated with product production, availability, access and efficacy. These challenges have provided ince...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Bonnie J. B., Ville, Jade, Blacquiere, Megan, Cen, Selena, Spirig, Rolf, Zuercher, Adrian W., Käsermann, Fabian, Branch, Donald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894239/
https://www.ncbi.nlm.nih.gov/pubmed/31801459
http://dx.doi.org/10.1186/s12865-019-0328-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894239/
https://www.ncbi.nlm.nih.gov/pubmed/31801459
http://dx.doi.org/10.1186/s12865-019-0328-6

Ejemplares similares